Alimentary TractOlder patients with eosinophilic esophagitis have high treatment response to topical steroids
Introduction
Eosinophilic esophagitis is a chronic immune/antigen-mediated clinicopathologic disease that impacts patients of all ages [1,2]. Because of symptoms, complications, and impact on quality of life, EoE results in a significant upper gastrointestinal morbidity and disease burden [3,4]. Over time, the esophageal inflammation may progress to a fibrostenotic phenotype, leading to more stricturing, dysphagia, and food impaction symptoms [5], [6], [7], [8]. Treatments for EoE can include proton-pump inhibitors, topical steroids, dietary elimination, and esophageal dilation [9,10]. While there are no FDA approved medications for the treatment of EoE in the U.S., a topical steroid has been approved in Europe and Canada, and multiple novel therapies are being explored [11], [12], [13], [14], [15], [16], [17].
Data suggest that EoE is increasing in incidence and prevalence with peak prevalence seen between the ages of 30–39 years old, with a subsequent decreased incidence as age increases [18]. With this and given that older EoE patients may have had the disease longer preceding diagnosis, elderly patients may be at risk for more severe fibrostenosis and less symptom response [19]. However, recent clinical trials have limited the upper age for inclusion. For example, trials of budesonide oral suspension capped the upper age at 40 or 55 years [14,15,20,21], two trials of biologics were capped at age 65 [12,17], and while a trial evaluating budesonide orodispesible tablets included patients aged 18–75, the average age was 37 years [16]. As such, the elderly EoE cohort, including their response to treatment, is poorly described.
Because EoE is chronic, the EoE patient population will age and be comprised of more elderly patients, making the disease more prevalent in the older population. The limited data exploring the older EoE population's use of topical corticosteroids (tCS) is a knowledge gap, and it is unknown whether they respond differently than non-elderly cohorts. Therefore, the aim of this study was to determine treatment outcomes to tCS in older EoE patients compared to younger EoE patients.
Section snippets
Methods
We conducted a retrospective cohort study of the University of North Carolina (UNC) EoE Clinicopathologic database, which has been previously described [22], [23], [24], [25], [26]. In brief, this database includes data from newly diagnosed EoE cases of all ages based on consensus guidelines at the time of their diagnosis [1], [2], [3],12]. For this study, patients were included if they had documented tCS treatment per clinical protocols and a follow-up endoscopy with biopsy to assess treatment
Baseline characteristics and comparison of <65-year-old cohort to ≥65-year-old cohort
We identified 467 newly diagnosed EoE patients who met inclusion criteria with tCS treatment. The overall mean age was 29 years old, with 152 patients (33%) under 18 years old and 12 patients (3%) 65 years or older (Table 1). The majority of the patients were Caucasian (83%), and 68% were male. Atopy, dysphagia symptoms, and typical endoscopic findings of EoE were also common. Comorbidities in the elderly subgroup included hypertension (58%), dyslipidemia (50%), benign prostatic hypertrophy
Discussion
EoE impacts patients of all ages and leads to significant morbidity and disease burden [1], [2], [3], [4]. Several modalities have been studied for the treatment of EoE, but topical steroids are the only treatment given a “strong” recommendation in recent guidelines [9,10]. Currently, scant data exist on treatment response in elderly EoE patients. Our main findings were that while patients ≥65 years old represented a relatively small proportion of EoE, they had a significantly higher histologic
Declaration of Competing Interest
Dr. Dellon is a consultant for Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Holoclara, Landos, Morphic, Nutricia, Parexel/Calyx, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, receives research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda, and has received an
Grant Support
This study was supported by NIH T35 DK007386 and T32 DK007634.
References (42)
- et al.
Eosinophilic Esophagitis: updated consensus recommendations for children and adults
J Allergy Clin Immunol
(2011) - et al.
Updated international consensus diagnostic criteria for Eosinophilic Esophagitis
- et al.
ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and Eosinophilic Esophagitis (EoE)
Am J Gastroenterol
(2013) - et al.
Health-care utilization, costs, and the burden of disease related to Eosinophilic Esophagitis in the United States
Am J Gastroenterol
(2015) - et al.
Natural history of Eosinophilic Esophagitis: a systematic review of epidemiology and disease course
Dis Esophagus
(2018) - et al.
Epidemiology and natural history of Eosinophilic Esophagitis
Gastroenterology
(2018) - et al.
A phenotypic analysis shows that Eosinophilic Esophagitis is a progressive fibrostenotic disease
Gastrointest Endosc
(2014) - et al.
Delay in diagnosis of Eosinophilic Esophagitis increases risk for stricture formation in a time-dependent manner
Gastroenterology
(2013) - et al.
AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of Eosinophilic Esophagitis
Gastroenterology
(2020) - et al.
Technical review on the management of Eosinophilic Esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters
Gastroenterology
(2020)
Emerging therapies for Eosinophilic Esophagitis
J Allergy Clin Immunol
RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with Eosinophilic Esophagitis
Gastroenterology
Anti–siglec-8 antibody for Eosinophilic gastritis and duodenitis
N Engl J Med
Budesonide oral suspension improves outcomes in patients with Eosinophilic Esophagitis: results from a phase 3 trial
Clin Gastroenterol Hepatol
Safety and efficacy of budesonide oral suspension maintenance therapy in patients with Eosinophilic Esophagitis
Clin Gastroenterol Hepatol
Efficacy of budesonide orodispersible tablets as induction therapy for Eosinophilic Esophagitis in a randomized placebo-controlled trial
Gastroenterology
Efficacy of dupilumab in a phase 2 randomized trial of adults with active Eosinophilic Esophagitis
Gastroenterology
Prevalence of Eosinophilic Esophagitis in the United States
Clin Gastroenterol Hepatol
A conceptual approach to understanding treatment response in Eosinophilic Esophagitis
Clin Gastroenterol Hepatol
Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with Eosinophilic Esophagitis
Gastroenterology
Long-term treatment of Eosinophilic Esophagitis with budesonide oral suspension
Clin Gastroenterol Hepatol
Cited by (9)
Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis
2024, Clinical Gastroenterology and HepatologyHigher Body Mass Index Is Associated With Decreased Treatment Response to Topical Steroids in Eosinophilic Esophagitis
2023, Clinical Gastroenterology and HepatologyCitation Excerpt :Another study assessed complete responders (<1 eos/hpf), finding tCS response to be more common in older age and in those with food allergies, whereas predictors of nonresponse were baseline dilation, presence of edema, and presence of hiatal hernia.37 Elderly patients (age, ≥65 y) also have been shown to be more tCS responsive.38 None of these aforementioned studies evaluated BMI.
Clinical Features and Treatment Response to Topical Steroids in Ethnic and Racial Minority Patients With Eosinophilic Esophagitis
2024, American Journal of GastroenterologyIncreasing Age at the Time of Diagnosis and Evolving Phenotypes of Eosinophilic Esophagitis Over 20 Years
2024, Digestive Diseases and SciencesRetrospective cohort study: Effect of age as a barrier to diagnosis of eosinophilic oesophagitis
2024, Alimentary Pharmacology and TherapeuticsA New Tool to Assess Disease Severity in Eosinophilic Esophagitis
2023, Gastroenterology and Hepatology
- 1
co-first authors.